spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hepatic encephalopathy 

 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Dec 2017
Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Feb 2016
Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
Biopharmaceuticals Generics Gastroenterology FDA
 HSMN NewsFeed - 30 Mar 2015
Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2013
Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2013
PBAC Approves XIFAXAN(R) (Rifaxamin α) 550 mg Cost Effectiveness in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Nov 2010
Hyperion Therapeutics Elects David W. Gryska to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2010
U.S. Food and Drug Administration Approves BARACLUDE(R) (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2010
FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2009
Hyperion Therapeutics Raises $60 Million Series C
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jun 2009
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2008
Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Arbios Announces It Has Suspended Operations
Devices
 HSMN NewsFeed - 12 May 2008
Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
Devices FDA
 HSMN NewsFeed - 28 Apr 2008
Hyperion Therapeutics Names Bruce F. Scharschmidt CMO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2008
Ocera Therapeutics Closes $35.5 Million Series C Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 4 Oct 2007
Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Devices FDA
 HSMN NewsFeed - 7 Sep 2007
Arbios Systems Publishes Positive Results From Completed Sepet(TM) Feasibility Clinical Trial
Devices
 HSMN NewsFeed - 5 Sep 2007
NEA Participates in $40M Investment in Hyperion Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Sep 2007
Hyperion Therapeutics Secures $40 Million In Series B Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Feb 2007
Salix Pharmaceuticals Acquires PEPCID(R) Oral Suspension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Oct 2006
Arbios Systems Announces Presentation of SEPET(TM) Clinical Data at the 57th Annual AASLD Meeting
Devices
 HSMN NewsFeed - 15 May 2006
Arbios Systems Presents Positive Interim Safety and Patient Outcome Results From the SEPET(TM) Liver Assist Device Clinical Trial
Devices
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
hepatic encephalopathy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.